One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Accesshttps://doi.org/10.1182/blood.v130.suppl_1.1299.1299
Copy DOI Journal: Blood |  Publication Date: Jun 25, 2021 |
Affiliation: Memorial Sloan Kettering Cancer Center, Cornell University, Harvard University, University of Colorado Denver, NewYork–Presbyterian Hospital, Northwestern University, The University of Texas MD Anderson Cancer Center, Agios Pharmaceuticals (United States), Massachusetts General HospitalContinuing Enasidenib Treatment for Patients with Mutant- IDH2 (m IDH2) Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Survival and Responses over Time
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
